Abstract
Background and objectives Quadrivalent live attenuated influenza vaccines (LAIV-4) offer an alternative to inactivated influenza vaccines (IIV) for children aged 2-17 years, but data on their comparative effectiveness are limited. This study assessed vaccination rates and real-world effectiveness of LAIV-4 and IIV in preventing influenza and influenza-like illness (ILI) in Italian children during the 2022-2023 and 2023-2024 seasons.
Methods We conducted a population-based cohort study of children aged 2-14 years from September 2022 to April 2024, using data from Pedianet, a pediatric primary care database of anonymized records from family pediatricians. Children vaccinated with LAIV-4 or IIV were compared to unvaccinated children. The primary outcome was any first influenza or ILI episode. Monthly vaccination incidence rates per 1,000 person-months were calculated for each vaccine type. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for vaccine effectiveness (VE) were estimated using adjusted mixed-effects Cox models.
Results A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children were included for the 2022-2023 and 2023-2024 seasons, respectively. Vaccination rates were 12.71 and 12.85 per 1,000 person-months, respectively. Compared to unvaccinated children, LAIV-4 had an overall effectiveness of 43% (95% CI, 32%-53%), while IIV effectiveness was 54% (95% CI, 46%-61%). In 2022-2023, LAIV-4 (38% [95% CI, 12%-56%]) and IIV (49% [95% CI, 37%-58%]) had comparable effectiveness. In 2023-2024, LAIV-4 (40% [95% CI, 25%-52%]) was slightly less effective than IIV (58% [95% CI, 44%-68%])(p=0.048).
Conclusions An overall moderate, comparable effectiveness of LAIV-4 and IIV in preventing influenza/ILI among Italian children was observed.
Article Summary A retrospective population-based cohort analysis showing moderate effectiveness of live attenuated influenza vaccines (LAIVs) in preventing influenza/influenza-like-illness in Italian children.
What’s Known on This Subject There is conflicting evidence on the effectiveness of the quadrivalent live attenuated influenza vaccine LAIV (LAIV-4) in the pediatric population.
What This Study Adds This population-based study assesses the effectiveness of LAIVs against influenza/influenza-like illness (ILI) among children in Italy in the post-COVID-19 influenza seasons using real-world data. Our findings document moderate protection provided by LAIVs against influenza/ILI in the 2022-2023 and 2023-2024 seasons.
Contributors Statement Page Dr. Vera Rigamonti performed the statistical analysis, interpreted the results, and drafted the initial manuscript;
Dr. Vittorio Torri conceptualized and designed the artificial intelligence algorithms; Dr. Daniele Donà contributed to data interpretation;
Drs Anna Cantarutti and Costanza Di Chiara, designed the study, contributed to the analysis plan, interpreted the results, supervised the project, and contributed to the manuscript writing;
Profs. Shaun K Morris, Francesca Ieva, and Carlo Giaquinto interpreted the results and critically reviewed the manuscript for important intellectual content.
All authors reviewed, edited, and approved the final version of the manuscript, authorized its submission for publication, and agree to be accountable for all aspects of the work.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is partially supported by CARICE (COVID-19 and Acute Respiratory Infections: the Clinical and Epidemiological changes in the pediatric population) project, which is funded by the Ministry of University and Research within the PRIN 2022 PNRR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Inclusion in the Pedianet database is voluntary, and parents/legal guardians must provide general consent for their children's anonymized data to be stored and used for research purposes. The Internal Scientific Committee of Societa' Serivizi Telematici Srl, the legal owner of Pedianet granted ethical approval of the study and access to the database.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* contributed as co-senior authors
A complete list of CARICE study group members appears in Appendix 1
Conflict of Interest Disclosures (includes financial disclosures): The authors have indicated that they have neither potential conflicts of interest nor financial relationships relevant to the article to disclose.
Funding/Support: This work is partially supported by CARICE (COVID-19 and Acute Respiratory Infections: the Clinical and Epidemiological changes in the pediatric population) project, which is funded by the Ministry of University and Research within the PRIN 2022 PNRR.
Data Availability
Data produced in the present study are available upon reasonable request to the corresponding author
Abbreviations
- IIV
- inactivated influenza vaccine
- LAIV
- live attenuated influenza vaccine quadrivalent LAIV (LAIV-4)
- ILI
- influenza-like illness
- FP
- family pediatrician
- VE
- vaccine effectiveness
- HR
- hazard ratio
- CI
- confidence interval
- PPIP
- special professional commitment service
